Dyslipidemia treatment: current considerations and unmet needs

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Lipid Metabolism

Background:

• Monotherapy with lipid-regulating drugs reduces atherosclerotic cardiovascular disease (ASCVD) risk by approximately 30% in dyslipidemic patients.
• Greater ASCVD risk reduction necessitates novel therapeutic strategies beyond current monotherapies.
• Emerging evidence supports combination drug therapy for enhanced lipoprotein management and ASCVD event reduction.

Purpose of the Study:

• To evaluate the efficacy of combination therapy in achieving ASCVD risk reduction exceeding 30%.
• To explore the synergistic effects of drugs with different lipid-modulating mechanisms.
• To highlight the potential of novel drug formulations and combination therapies.

Main Methods:

• Review of clinical trial evidence on lipid-regulating drug monotherapy and combination therapy.
• Analysis of studies investigating the mechanisms of action for niacin, statins, and other lipid-lowering agents.
• Examination of preliminary data on combination therapy outcomes in dyslipidemic patients.

Main Results:

• Niacin increases high-density lipoproteins (HDL) by inhibiting catabolism and decreases very-low- and low-density lipoproteins (VLDL/LDL) by inhibiting triglyceride synthesis.
• Combination therapy with statins and niacin demonstrates safe and effective dyslipidemia correction.
• Combination therapy yields ASCVD risk reduction significantly greater than the 30% observed with monotherapy.

Conclusions:

• Combination therapy, particularly with statins and niacin, offers superior ASCVD risk reduction compared to monotherapy.
• Newer drugs and formulations with distinct mechanisms of action are becoming available.
• Further clinical trials are essential to validate combination therapies for substantially reducing ASCVD incidence.